首页> 外文期刊>Journal of Veterinary Internal Medicine >Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke
【24h】

Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke

机译:非诺多opa对中暑犬急性肾损伤的控制作用及其对肾功能的影响

获取原文
获取外文期刊封面目录资料

摘要

Background Acute kidney injury (AKI) is common in dogs, but evidence of efficacy of its treatment is lacking. Objective To evaluate the efficacy of fenoldopam in the management of AKI. Animals Forty dogs with naturally occurring heatstroke. Methods Dogs were prospectively enrolled and divided into treatment and the placebo groups (fenoldopam, constant rate infusion [CRI] of 0.1 μg/kg/min or saline, respectively). Urine production (UP) was measured using a closed system. Urinary clearances were performed at 4, 12, and 24 hours after presentation to estimate the effect of fenoldopam on UP, glomerular filtration rate (GFR) and sodium fractional excretion (NaFE). Results At presentation, severity of heatstroke, based on a previously developed scoring system, was similar between the study groups, but was significantly worse in nonsurvivors compared with survivors. Fenoldopam administration was not associated with hypotension. Overt AKI was diagnosed, based on the International Renal Interest Society guidelines in 22/40 (55%) of the dogs. Overall, 14/40 dogs (35%) died, with no significant ( P =?.507) mortality rate difference between the fenoldopam (6/20 dogs; 30%) and placebo (8/20; 40%) groups. The proportion of dogs with AKI did not differ between the fenoldopam and the placebo groups (9/20; 45% versus 13/20; 65%, respectively; P =?.204). There were no differences in UP, GFR, and NaFE between the fenoldopam and the placebo groups. Conclusion and Clinical Importance Fenoldopam CRI at 0.1 μg/kg/min did not have a clinically relevant effect on kidney function parameters in dogs with severe heatstroke‐associated AKI.
机译:背景技术急性肾损伤(AKI)在狗中很常见,但缺乏其治疗功效的证据。目的评价非诺多m治疗AKI的疗效。动物40条自然中暑的狗。方法前瞻性招募犬,将其分为治疗组和安慰剂组(非诺多m,恒速输注[CRI]分别为0.1μg/ kg / min或生理盐水)。使用密闭系统测量尿液产量(UP)。出现后第4、12和24小时进行尿清除,以评估非诺多m对UP,肾小球滤过率(GFR)和钠分数排泄(NaFE)的影响。结果在报告中,研究组之间基于以前开发的评分系统的中暑严重程度相似,但与幸存者相比,非幸存者的中暑严重程度明显降低。非诺多m的给药与低血压无关。根据国际肾脏兴趣协会指南,在22/40(55%)的狗中诊断出明显的AKI。总的来说,有14/40只狗(35%)死亡,在非诺多6(6/20只狗; 30%)和安慰剂(8/20; 40%)组之间,死亡率没有显着差异(P = ?. 507)。在非诺多m和安慰剂组之间,患有AKI的狗的比例没有差异(分别为9/20; 45%比13/20; 65%; P = ?. 204)。非诺多m组和安慰剂组之间的UP,GFR和NaFE没有差异。结论和临床重要性非诺多m CRI 0.1μg/ kg / min对重症中暑相关AKI犬的肾功能参数没有临床相关影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号